EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation

Hong Zhou, Lixia Guan, Guoqiang Lin, Xiaotian Yang, Xingxia Zhang, Yejun Si, Yanming Zhang, Juan Chen

Journal of Enzyme Inhibition and Medicinal Chemistry · 2025

DOI: 10.1080/14756366.2025.2563601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2025. Verfasst von Hong Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Proto-Oncogene Proteins, Protein Kinase Inhibitors. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the research project of Huai’an Science and Technology Bureau, Huai’an Health Commission Research General Project, Jiangsu Commission of Health scientific research project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma, a hematological malignancy, shows PLK1 overexpression in cells correlates with poor prognosis, suggesting PLK1 as a potential therapeutic target. In this study, we discovered five peptides (PLs 1-5) targeting the polo box domain (PBD) of PLK1 through an integrated virtual screening strategy. MST assays confirmed that PLs 1-5 had strong binding affinity for PLK1, especially PL-1 (Kd = 3.11 ± 0.05 nM). Meanwhile, the kinase selectivity assay showed that the PL-1 had no significant inhibitory effects on a panel of other kinases. Molecular dynamics simulation further demonstrated the structural stability of PL-1 and PLK1 complex. Notably, PL-1 displayed potent antiproliferative efficacy against U266 multiple myeloma cells (IC50 = 0.09 ± 0.01 µM). PL-1 showed high intracellular uptake capacity. In addition, PL-1 exhibited good biostability in human serum and liver microsomes. Taken together, PL-1 is a potent and highly selective antitumor agent with considerable therapeutic promise for multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsProtein Kinase InhibitorsMolecular Dynamics SimulationMolecular Docking SimulationAntineoplastic AgentsPeptidesHumansPolo-Like Kinase 1Cell ProliferationStructure-Activity RelationshipMolecular StructureDrug Screening Assays, AntitumorDose-Response Relationship, DrugCell Line, TumorPharmacophore

Stichwörter der Autor:innen

Multiple myelomapolo box domain (PBD)polo-like kinase 1 (PLK1)structure-based virtual screening

Substanzen

Protein Serine-Threonine KinasesPolo-Like Kinase 1Cell Cycle ProteinsProto-Oncogene ProteinsProtein Kinase InhibitorsAntineoplastic AgentsPeptides

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
  • Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
  • Department of Hematology, Siyang Hospital of Traditional Chinese Medicine, Su Qian, China.

Förderung

  • the research project of Huai’an Science and Technology Bureau
  • Huai’an Health Commission Research General Project
  • Jiangsu Commission of Health scientific research project
  • Xuzhou Medical University Affiliated Hospital Development Fund General Project

Zitieren

APA

Zhou, H., Guan, L., Lin, G., Yang, X., Zhang, X., Si, Y., Zhang, Y., & Chen, J. (2025). Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2025.2563601

Vancouver

Zhou H, Guan L, Lin G, Yang X, Zhang X, Si Y, et al. Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. 2025. doi:10.1080/14756366.2025.2563601

BibTeX
@article{Zhou2025,
  author = {Zhou, Hong and Guan, Lixia and Lin, Guoqiang and Yang, Xiaotian and Zhang, Xingxia and Si, Yejun and Zhang, Yanming and Chen, Juan},
  title = {Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2025},
  doi = {10.1080/14756366.2025.2563601}
}
Kostenlos starten →